Insulin Out-of-Pocket Cost Caps Do Not Increase Insulin Use
By Elana Gotkine HealthDay Reporter
TUESDAY, March 26, 2024 -- Insulin out-of-pocket (OOP) cost caps are associated with a reduction in insulin OOP costs, but no increase in insulin use, according to a study published online March 26 in the Annals of Internal Medicine.
Laura F. Garabedian, Ph.D., M.P.H., from Harvard Medical School and the Harvard Pilgrim Health Care Institute in Boston, and colleagues conducted a pre-post study with a control group to examine the effect of state insulin OOP caps on insulin use and OOP costs among patients with diabetes. Data were included from eight states implementing insulin OOP caps of $25 to $30, $50, or $100 in January 2021 and 17 control states.
The researchers found that in the overall population, state insulin caps were not associated with changes in insulin use (relative change in fills per month, 1.8 percent). In intervention states, insulin users had a 17.4 percent relative reduction in insulin OOP costs, which was mainly driven by reductions among health savings account (HSA) enrollees; among nonaccount plan members, there were no differences seen in OOP costs. Insulin OOP cost reductions were larger (40.0 percent) in association with more generous ($25 to $30) state insulin OOP caps, which was mainly driven by larger reductions in those with HSA plans.
"Other policies might be needed to improve access to affordable insulin among commercially insured patients with diabetes who have cost-related underuse," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.